Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations.
Fiche publication
Date publication
février 2019
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr VERNEREY Dewi, Dr VIENOT Angélique
Tous les auteurs :
Neuzillet C, Casadei Gardini A, Brieau B, Vivaldi C, Smolenschi C, Brandi G, Tougeron D, Filippi R, Vienot A, Silvestris N, Pointet AL, Lonardi S, Rousseau B, Scartozzi M, Dahan L, Aprile G, Boussaha T, Malka D, Crusz SM, Le Sourd S, Meurisse A, Lièvre A, Vernerey D, , Evesque L, Heurgué A, Desramé J, Lecomte T, Cacheux W, Bachet JB, Phelip JM, Hautefeuille V, Hammoudi N, Mary F, Locher C, Bidault-Thirot A, Marthey L, Touchefeu Y, Moulin V, Zaanan A, Taïeb J, , Casagrande M, Murgioni S, Santini D, Fornaro L, Montagnani F, Leone F, Faloppi L, Giommoni E, Lutrino SE, Palloni A, Brunetti O, Bergamo F, Vasile E, , Malka D,
Lien Pubmed
Résumé
The benefit of second-line chemotherapy (L2) over standard first-line (L1) gemcitabine plus cisplatin (GEMCIS) or oxaliplatin (GEMOX) chemotherapy in advanced biliary tract cancer (aBTC) is unclear. Our aim was to identify and validate prognostic factors for overall survival (OS) with L2 in aBTC to guide clinical decisions in this setting.
Référence
Eur. J. Cancer. 2019 Feb 28;111:94-106